Transcatheter Aortic Valve Replacement in the USA

Transcatheter aortic valve replacement (TAVR) is the preferred treatment for severe aortic stenosis (AS) in patients considered to be extreme-risk surgical risk and is an alternative to surgical aortic valve replacement (SAVR) in high-risk patients. Currently, the balloon-expandable SAPIEN valve and the self-expanding CoreValve are approved for TAVR in the USA. An additional four TAVR valves (Lotus, Portico, Direct Flow, and JenaValve) are in clinical trials in the USA.